Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00043888 |
Antiretroviral Therapy (ART) naive subjects will be enrolled in this clinical research study to test the safety and tolerability of fosamprenavir with or without ritonavir in combination TRIZIVIR and COMBIVIR. Subjects will receive 24 weeks of therapy.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: fosamprenavir Drug: COMBIVIR Drug: ritonavir Drug: TRIZIVIR |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety Study |
Official Title: | A Phase IIIb/IV, Randomized, Open Label, Multicenter, Pilot Trial to Explore the Safety and Tolerability of GW433908 +/- Ritonavir (1400mg Twice Daily or 700mg/100mg Twice Daily) When Used in Combination With a Zidovudine-Containing Regimen (TRIZIVIR or COMBIVIR Twice Daily) Over a 24 Week Period in Antiretroviral Therapy Naive HIV-1 Infected Subjects. |
Estimated Enrollment: | 60 |
Study Start Date: | January 2002 |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arkansas | |
GSK Clinical Trials Call Center | |
Little Rock, Arkansas, United States, 72205 | |
United States, California | |
GSK Clinical Trials Call Center | |
Long Beach, California, United States, 90813 | |
GSK Clinical Trials Call Center | |
Newport Beach, California, United States, 92663 | |
GSK Clinical Trials Call Center | |
San Diego, California, United States, 92101 | |
United States, Colorado | |
GSK Clinical Trials Call Center | |
Denver, Colorado, United States, 80220 | |
United States, District of Columbia | |
GSK Clinical Trials Call Center | |
Washington, District of Columbia, United States, 20036 | |
United States, Florida | |
GSK Clinical Trials Call Center | |
Altamonte Springs, Florida, United States, 32701 | |
GSK Clinical Trials Call Center | |
Fort Lauderdale, Florida, United States, 33316 | |
GSK Clinical Trials Call Center | |
Fort Lauderdale, Florida, United States, 33308 | |
GSK Clinical Trials Call Center | |
Fort Lauderdale, Florida, United States, 33334 | |
United States, Georgia | |
GSK Clinical Trials Call Center | |
Atlanta, Georgia, United States, 30339 | |
United States, North Carolina | |
GSK Clinical Trials Call Center | |
Greenville, North Carolina, United States, 27858 | |
United States, Pennsylvania | |
GSK Clinical Trials Call Center | |
Philadelphia, Pennsylvania, United States, 19107 | |
France | |
GSK Clinical Trials Call Center | |
Paris, France, 75679 | |
GSK Clinical Trials Call Center | |
Paris, France, 75475 | |
GSK Clinical Trials Call Center | |
Lyon, France, 69437 | |
United Kingdom | |
GSK Clinical Trials Call Center | |
Manchester, United Kingdom, M8 6RL | |
GSK Clinical Trials Call Center | |
London, United Kingdom, SE5 9RS |
Study Director: | GSK Clinical Trial, MD | GlaxoSmithKline |
Study ID Numbers: | AZL30006 |
Study First Received: | August 14, 2002 |
Last Updated: | March 6, 2006 |
ClinicalTrials.gov Identifier: | NCT00043888 |
Health Authority: | United States: Food and Drug Administration |
fosamprenavir ritonavir COMBIVIR TRIZIVIR abacavir |
lamivudine zidovudine HIV protease inhibitors |
Virus Diseases Sexually Transmitted Diseases, Viral Fosamprenavir Ritonavir HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Lamivudine Zidovudine Abacavir Retroviridae Infections Immunologic Deficiency Syndromes |
Anti-Infective Agents RNA Virus Infections HIV Protease Inhibitors Slow Virus Diseases Anti-HIV Agents Immune System Diseases Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors |
Infection Antiviral Agents Pharmacologic Actions Protease Inhibitors Anti-Retroviral Agents Therapeutic Uses Lentivirus Infections |